ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1523 • ACR Convergence 2022

    Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement

    Darya S. Jalaledin1, Hajar El Kamouni2, Alexandra Albert3, Sabrina Hoa4, Josiane Bourre-Tessier5, Eric Rich5, Jean-Richard Goulet6, Martial Koenig7, Minoru Satoh8, Marvin Fritzler9, May Choi10, Yves Troyanov11, Jean-Luc Senécal, MD12 and Océane Landon-Cardinal5, 1Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, 2Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, 3Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, 4University of Montreal, Montréal, QC, Canada, 5Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 6Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, 7Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 8Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, 9University of Calgary, Calgary, AB, Canada, 10Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 11Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 12Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada

    Background/Purpose: RNA-binding region containing 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous studies, systemic sclerosis (SSc) patients who…
  • Abstract Number: 1520 • ACR Convergence 2022

    Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre

    Nina Goldman1, Aoife Tynan2, Shivani Shah2, Claire Beesley1, Rizgar Mageed3, Chris Denton1 and Voon Ong4, 1University College London, London, United Kingdom, 2Division of Medicine, Department of Rheumatology, University College London, London, United Kingdom, 3Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, 4UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…
  • Abstract Number: 1502 • ACR Convergence 2022

    Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams

    Evan Siegel1, Amit Garg2, Jeffrey Carter3, Laura Simone4 and Marykate Nelson5, 1Georgetown University School of Medicine, Washington, DC, 2Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, 3PRIME Education, Boynton Beach, FL, 4PRIME Education, Omaha, NE, 5PRIME Education, Drexel Hill, PA

    Background/Purpose: The optimal care of psoriatic arthritis (PsA) requires effective collaboration between rheumatology and dermatology teams. We executed an initiative to identify gaps and inform…
  • Abstract Number: 1478 • ACR Convergence 2022

    Urine ALCAM Is a Strong Predictor of Lupus Nephritis

    Dalena Chu1, Noa Schwartz2, Jeanette Ampudia1, Joel Guthridge3, Judith James3, Jill Buyon4, Stephen Connelly1, Maple Fung1, Cherie Ng1, AMP SLE/RA consortium5, Michelle Petri6, Chandra Mohan7 and Chaim Putterman8, 1Equillium, Inc., La Jolla, CA, 2Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4NYU Grossman School of Medicine, New York, NY, 5Accelerating Medicines Partnership, Los Angeles, CA, 6Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 7University of Houston, Houston, TX, 8Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…
  • Abstract Number: 1531 • ACR Convergence 2022

    Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON

    Yannick Allanore1, Madelon Vonk2, Oliver Distler3, Arata Azuma4, Maureen Mayes5, Alexandra James6, Veronika Kohlbrenner7, Margarida Alves8, Dinesh Khanna9 and Kristin Highland10, 1Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 2Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 4Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 6Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 10Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH

    Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
  • Abstract Number: 1530 • ACR Convergence 2022

    Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality

    Aditi Patel1, Chao Zhang1 and Soumya Chatterjee2, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Richmond Heights, OH

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication in patients with systemic sclerosis (SSc), characterized by accelerated hypertension and acute kidney injury. ACE inhibitors…
  • Abstract Number: 1534 • ACR Convergence 2022

    Blood Flow Assessment of Digital Arterioles and Capillaries in Systemic Sclerosis Patients Using Ultra-high Resolution Doppler Ultrasounds

    Pietro Francesco Bica1, Riccardo Picasso2, Federico Pistoia2, Federico Zaottini2, Sara Sanguinetti2, Francesca Bovis3, Marta Ponzano3, Carmen Pizzorni1, sabrina Paolino1, Alberto Sulli1, Emanuele Gotelli1, Carlo Martinoli2 and Maurizio Cutolo1, 1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, 2Department of Health Sciences (DISSAL), University of Genova, Genova, Italy - IRCCS San Martino Polyclinic Hospital, Genova, Italy, 3Department of Health Sciences (DISSAL), University of Genova, Genova, Italy

    Background/Purpose: Systemic sclerosis (SSc) is a chronic connective tissue disease, characterized by the early occurrence of vasculopathy [1], easily detected by nailfold videocapillaroscopy (NVC) [2].…
  • Abstract Number: 1533 • ACR Convergence 2022

    Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees

    Alexandru Garaiman1, Carina Mihai1, Rucsandra Dobrota1, cosimo bruni2, Muriel Elhai1, Suzana Jordan1, Lea Stamm3, Anna-Maria Hoffmann-vold4, Oliver Distler1 and Mike Becker1, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2University of Florence, Florence, Italy, 3Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 4Oslo University Hospital, Oslo, Norway

    Background/Purpose: Some gastrointestinal (GI) and nutritional factors are associated with the presence of interstitial lung disease related to systemic sclerosis (SSc-ILD). However, there are many…
  • Abstract Number: 1535 • ACR Convergence 2022

    Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis

    Jessica Fairley1, Laura Ross2, Alannah Quinlivan3, Dylan Hansen4, Elizabeth Paratz5, Wendy Stevens4, Peter M Kistler6, Andre La Gerche7 and Mandana Nikpour8, 1The University of Melbourne, Melbourne, Australia, 2The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 3St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, 4St Vincent's Hospital Melbourne, Melbourne, Australia, 5The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, 6The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, 7The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, 8The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
  • Abstract Number: 1532 • ACR Convergence 2022

    The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging

    sanya Chhikara1, Adinan Kanda2, mohamed Ismail2, Fredrick Ogugua2, Rejowana Rouf2, khaled Ismail2, Parag Bawaskar2, Jerry Molitor2 and Chetan Shenoy2, 1University of Minnesota, New York, NY, 2University of Minnesota, Minneapolis, MN

    Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
  • Abstract Number: 1538 • ACR Convergence 2022

    Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes

    Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH

    Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
  • Abstract Number: 1537 • ACR Convergence 2022

    Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

    Line Iversen1, Ole Østergaard2, Tina Friis3, susanne Ullman4, Søren Jacobsen5 and Jesper Olsen2, 1Department of Dermatology, Odense University Hospital., Odense, Denmark, 2Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, 3Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 4Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, 5Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark

    Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
  • Abstract Number: 1540 • ACR Convergence 2022

    Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis

    Luise Schumacher1, Sebastian Klapa2, Antje Mueller3 and Gabriela Riemekasten4, 1University of Lübeck, Lübeck, Germany, 2Universityhospital Schleswig-Holstein; University of Lübeck; Clinic of Rheumatology and Clinical Immunology, Luebeck, Germany, 3University Hospital Schleswig-Holstein (UKSH), Lübeck, 4University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany

    Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…
  • Abstract Number: 1542 • ACR Convergence 2022

    Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry

    Shery Susan Philip1, Ramya Janardana1, Revanesh S Mirji1, Chengappa Kavadichanda2, Devender Bairwa3, Geetabali Sircar4, Parasar Ghosh5, Anupam Wakhlu6, Padmanabha Shenoy7, Sumithra Selvam8 and Vineeta Shobha1, 1St. John’s Medical College Hospital, Bangalore, India, 2JIPMER, Pondicherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 4Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, 5Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 6Apollo Medics Super Speciality Hospitals, Lucknow, India, 7Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, 8Division of Epidemiology and Biostatistics, St. John’s Research Institute, St. John's Medical College Hospital, Bangalore, India

    Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…
  • Abstract Number: 1545 • ACR Convergence 2022

    Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica

    Despina Michailidou1, Linda Johansson2, Runa Kuley1, TING WANG1, Payton Hermanson1, Solbritt Rantapää-Dahlqvist2 and Christian Lood1, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden

    Background/Purpose: Neutrophils are important in host defense. However, neutrophil activation has also been involved in the immunopathogenesis of several autoimmune diseases due to their many…
  • « Previous Page
  • 1
  • …
  • 651
  • 652
  • 653
  • 654
  • 655
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology